Clinical trials: Graft -Versus-host-disease
Wounds
Clinical Validation of a 'Hand-held' Fluorescence Digital Imaging Device for Wound Care Applications
The primary objective of this clinical study is to evaluate the use and effectiveness of our 'handheld' fluorescence digital imaging device platform for real-time non-invasive clinical monitoring of chronic wounds for healing and…
- Trial name
- NCT01378728
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- University Health Network, Toronto
Chronic, Non-neuropathic Back Pain
Effects of Behavioral Interventions on Mechanisms of Pain Regulation and Hedonic Regulation
The overarching aim of this project is to conduct a randomized controlled study to determine whether Mindfulness-Oriented Recovery Enhancement (MORE) vs.
- Trial name
- NCT02935465
- Testing
- Mindfulness-Oriented Recovery Enhancement (MORE), Support Group
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Utah
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Sirolimus, tacrolimus, and methotrexate may be effective in preventing acute graft-versus-host disease in patients who are undergoing donor stem cell transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00089037
- Testing
- methotrexate, sirolimus, tacrolimus
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Graft Versus Host Disease
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
This is an open-label, single group, Phase 1/2, 1-arm study for treatment of children aged 1 to <18 years with active moderate-to-severe cGVHD that is refractory to or recurred after at least 2 prior lines of systemic therapy for…
- Trial name
- schoolROCK (NCT07116031)
- Testing
- Belumosudil
- Where
- 35 sites in United States, Belgium and 11 more
- Volunteers
- 37 people
- Sponsor
- Sanofi
Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF)
Managed Access Programs for INC424, Ruxolitinib
The purpose of this registration is to list Managed Access Programs (MAPs) related to INC424, Ruxolitinib
- Conditions
- Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF), Thrombocythemia Myelofibrosis (PET-MF), Severe/Very Severe COVID-19 Illness
- Trial name
- NCT04745637
- Testing
- Ruxolitinib
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Myeloid, Chronic-phase, Leukemia, Lymphoblastic, Acute, Philadelphia-positive
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
The purpose of this clinical research study is to understand the safety and efficacy of BMS-354825 in patients with chronic, accelerated, or blast phase chronic myelogenous leukemia (CML) or Philadelphia positive acute…
- Trial name
- NCT00103701
- Testing
- Dasatinib
- Where
- 2 sites in United States
- Sponsor
- Bristol-Myers Squibb
Graft Versus Host Disease, Hematopoietic Cell Transplantation Recipient
Gluten Free Diet in Preventing Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant
This pilot clinical trial studies how well a gluten free diet works in preventing graft versus host disease in patients who are undergoing a donor stem cell transplant.
- Trial name
- NCT03102060
- Testing
- Dietary Intervention, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Rutgers, The State University of New Jersey
Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Normal Ejection Fraction
Chronic Exogenous Ketosis in HFpEF
The goal of this clinical research study is to test what effects a ketone drink will have in people with heart failure with preserved ejection fraction (HFpEF), including on exercise and heart function.
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Normal Ejection Fraction, Heart Failure, Diastolic
- Trial name
- NCT06937320
- Testing
- Exogenous Ketone Drink
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Left-Hemisphere Stroke
Brain Markers Predicting Reading Recovery After Stroke
For millions of stroke survivors acquired reading deficits represent a significant handicap preventing them from returning to work or continuing their education.
- Trial name
- NCT03845686
- Testing
- Perfusion functional Magnetic Resonance Imaging (perfusion fMRI)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Kessler Foundation
Graft Versus Host Disease, Acute, Endothelial Dysfunction
Origin of CEC in Patients After Allo-HSCT
We believe that CEC, besides coming from cells shedding from patient vasculature, could partly belong to donor, originating from the cellular graft.
- Conditions
- Graft Versus Host Disease, Acute, Endothelial Dysfunction, Immune Tolerance
- Trial name
- DCEC-PIANO (NCT04038827)
- Testing
- D-CEC counting
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral stem cell transplant helps stop the growth of abnormal and cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00346359
- Testing
- anti-thymocyte globulin, busulfan, fludarabine phosphate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Graft-versus-host-disease
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
This study will be conducted to compare Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy.
- Trial name
- NCT06821542
- Testing
- INCA034176, Best Available Therapy (BAT)
- Where
- 130 sites in Austria, Belgium and 14 more
- Volunteers
- 9 people
- Sponsor
- Incyte Corporation
Acute Graft Versus Host Disease
Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
To determine a safe and effective dose of pentostatin in steroid-refractory aGvHD and to identify the minimal effective dose of pentostatin defined as the lowest dose that produces a response in 20% or more of patients while…
- Trial name
- NCT00032773
- Testing
- pentostatin for injection
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Graft-Versus-Host Disease
Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease
This study will evaluate the response rate to treatment with pentostatin in steroid-refractory acute graft versus host disease.
- Trial name
- NCT00201786
- Testing
- Pentostatin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Graft Vs Host Disease
Ruxolitinib for Steroid-refractory GVHD
Steroid-refractory acute GVHD (srGVHD) is one of the causes of mortality after allogeneic stem cell transplantation, while steroid-refractory chronic GVHD significantly increases morbidity, aggravates quality of life and may also…
- Trial name
- NCT02997280
- Testing
- Ruxolitinib Oral Tablet
- Where
- Russia
- Volunteers
- 75 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Chronic Radiation Dermatitis
Pilot Study of the Effect of Laser on Reversing Chronic Radiation Injury
Radiotherapy, an essential modality in cancer treatment, frequently induces a fibrotic process in the skin which can lead to increased risk of malignancy, poor wound healing, pain and limitation of movement, and permanent loss of…
- Trial name
- NCT01910818
- Testing
- Fractional CO2 laser treatment, No treatment
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Condition After Allogenic Peripheral Stem Cell Transplantation (SCT)
PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood
In this prospective study is to examine whether the use of everolimus in patients after allogeneic SCT as part of GVHD prophylaxis for a further review in clinical studies is appropriate.
- Trial name
- NCT01509560
- Testing
- Everolimus
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Leukemia, Chronic Myelogenous Leukemia
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
The goal of this clinical research study is to learn if giving a kind of immune cell called natural killer (NK) cells after chemotherapy will improve the response to a stem cell transplant in patients with CML.
- Trial name
- NCT01390402
- Testing
- Fludarabine, Busulfan, NK cell infusion:
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Neuropathic Pain
Oral Ketamine Administration in Patients With Peripheral Neuropathic Pain
Nowadays, available drugs cannot always produce pain relief in patients with neuropathic pain disease. It is believed that drugs acting as antagonists of the N-methyl-D-aspartic acid (NMDA) receptor may have been efficient in the…
- Trial name
- KETACLUD (NCT00961194)
- Testing
- Ketamine
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Toulouse
Graft-versus-host Disease, Relapse
Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation
Infusion of Mesenchymal Stem Cell (MSC) at day of recovery after bone marrow transplant (BMT) for patients with AL, AA and MM for acute Graft-versus-host Disease (GVHD) prophylaxis and treatment.
- Trial name
- NCT01941394
- Testing
- Mesenchymal stem cells
- Where
- Russia
- Volunteers
- 70 people
- Sponsor
- National Research Center for Hematology, Russia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.